Abstract
Invasive fungal infections are serious complications of cancer therapy. We present a case report of a 12-year-old boy diagnosed with abdominal non-Hodgkin lymphoma and fecal and Candida peritonitis during induction chemotherapy. The invasive mycosis was managed using a combined approach of systemic antifungal agents including efungumab and surgical interventions. Efungumab, a recombinant antibody that inhibits extracellular heat shock protein 90, was used in combination with amphotericin B colloid dispersion after the failure of standard approaches.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Abdominal Neoplasms / complications*
-
Abdominal Neoplasms / drug therapy
-
Amphotericin B / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antifungal Agents / administration & dosage*
-
Candidiasis / drug therapy*
-
Child
-
Drug Therapy, Combination
-
HSP90 Heat-Shock Proteins / antagonists & inhibitors*
-
Humans
-
Lymphoma, Non-Hodgkin / complications*
-
Lymphoma, Non-Hodgkin / drug therapy
-
Male
-
Peritonitis / drug therapy*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antifungal Agents
-
HSP90 Heat-Shock Proteins
-
Amphotericin B
-
efungumab